Chang Gung Medical Foundation, Linkou Branch Patent applications |
Patent application number | Title | Published |
20150366912 | APPLICATION AND PHARMACEUTICAL COMPOSITION OF PREACTIVATED AND DISAGGREGATED SHAPE-CHANGED PLATELETS - Preactivated and disaggregated shape-changed platelets, fixed shape-changed platelets, and a pharmaceutical composition thereof are used for treating acute and emergent inflammatory disease in a dosage of 1×10 | 12-24-2015 |
20150104436 | APPLICATION AND PHARMACEUTICAL COMPOSITION OF PREACTIVATED AND DISAGGREGATED SHAPE-CHANGED PLATELETS - Preactivated and disaggregated shape-changed platelets, fixed shape-changed platelets, and a pharmaceutical composition thereof are used for treating acute and emergent inflammatory disease in a dosage of 1×10 | 04-16-2015 |
20140315222 | METHOD FOR MEASURING SIALIC ACID IN IMMUNOGLOBULIN G AND IMMUNOGLOBULIN G ANTI-DOUBLE-STRANDED DNA ANTIBODIES - A method for measuring the amount of sialic acid in immunoglobulin G and immunoglobulin G anti-ds DNA antibodies is disclosed. The method for measuring the amount of sialic acid in immunoglobulin G in the present invention uses culture fluid, blood, plasma, or serum to directly measure the amount of sialic acid in immunoglobulin G. Also, using a mouse monoclonal antibody immunoglobulin G as a standard, which is diluted from 1000 ng/ml to 15.625 ng/ml in phosphate buffered saline (PBS), produces good results. The method for measuring the amount of sialic acid in immunoglobulin G anti-ds DNA antibodies has never been done and the present invention produces good results as well. | 10-23-2014 |
20140242591 | METHOD OF DIAGNOSING AND PREVENTING PNEUMOCOCCAL DISEASES USING PNEUMOCOCCAL NEURAMINIDASES - A method of providing protection against pneumococcal infection in a subject is disclosed. The method includes steps of administering to the subject a composition that includes combination of three recombinant pneumococcal neuraminidases: NanA, NanB, and NanC of | 08-28-2014 |
20140193838 | METHOD FOR MEASURING SIALIC ACID IN IMMUNOGLOBULIN G AND IMMUNOGLOBULIN G ANTI-DOUBLE-STRANDED DNA ANTIBODIES - A method for measuring the amount of sialic acid in immunoglobulin G and immunoglobulin G anti-ds DNA antibodies is disclosed. The method for measuring the amount of sialic acid in immunoglobulin G in the present invention uses culture fluid, blood, plasma, or serum to directly measure the amount of sialic acid in immunoglobulin G. Also, using a mouse monoclonal antibody immunoglobulin G as a standard, which is diluted from 1000 ng/ml to 15.625 ng/ml in phosphate buffered saline (PBS), produces good results. The method for measuring the amount of sialic acid in immunoglobulin G anti-ds DNA antibodies has never been done and the present invention produces good results as well. | 07-10-2014 |
20130078259 | METHOD OF DIAGNOSING AND PREVENTING PNEUMOCOCCAL DISEASES USING PNEUMOCOCCAL NEURAMINIDASES - A method of providing protection against pneumococcal infection in a subject is disclosed. The method includes steps of administering to the subject a composition that includes combination of three recombinant pneumococcal neuraminidases: NanA, NanB, and NanC of | 03-28-2013 |
20120253376 | NATURAL ORIFICE TRANSLUMENAL ENDOSCOPIC SURGERY (NOTES) DEVICE - A natural orifice transluminal endoscopic surgery (NOTES) device is provided with a puncture needle including a puncture end, an intermediate protruding safety stud, and a positioning projection on an outer surface; dilator sheaths each including tapered first diameters, an insert member at one end, a limiting shoulder at the other end, a positioning protrusion on an outer surface, and a groove on an inner surface; working sheaths each having a plurality of tapered second diameters and including a positioning protuberance on an outer surface and a trough on an inner surface; and a tool member including a shaft having a graduation on an outer surface, and an operating head threadedly secured to the shaft. | 10-04-2012 |
20120225795 | PROTEIN MARKERS FOR DETECTING LIVER CANCER AND METHOD FOR IDENTIFYING THE MARKERS THEREOF - The present invention relates to the diagnosis of liver cancer. It discloses the use of protein ERBB3 and protein IGFBP2 in the diagnosis of liver cancer. It relates to a method for diagnosis of liver cancer from a liquid sample, derived from an individual by measuring ERBB3 protein and IGFBP2 protein in the sample. Measurement of ERBB3 protein and IGFBP2 protein can, e.g., be used in the early detection or diagnosis of liver cancer. | 09-06-2012 |
20120225441 | PROTEIN MARKERS FOR DETECTING LIVER CANCER AND METHOD FOR IDENTIFYING THE MARKERS THEREOF - The present invention relates to the diagnosis of liver cancer. It discloses the use of protein ERBB3 and protein IGFBP2 in the diagnosis of liver cancer. It relates to a method for diagnosis of liver cancer from a liquid sample, derived from an individual by measuring ERBB3 protein and IGFBP2 protein in the sample. Measurement of ERBB3 protein and IGFBP2 protein can, e.g., be used in the early detection or diagnosis of liver cancer. | 09-06-2012 |
20120225439 | PROTEIN MARKERS FOR DETECTING LIVER CANCER AND METHOD FOR IDENTIFYING THE MARKERS THEREOF - The present invention relates to the diagnosis of liver cancer. It discloses the use of protein ERBB3 and protein IGFBP2 in the diagnosis of liver cancer. It relates to a method for diagnosis of liver cancer from a liquid sample, derived from an individual by measuring ERBB3 protein and IGFBP2 protein in the sample. Measurement of ERBB3 protein and IGFBP2 protein can, e.g., be used in the early detection or diagnosis of liver cancer. | 09-06-2012 |
20120095325 | TREATMENT OF BRAIN DISEASES VIA ULTRASOUND/MAGNETIC TARGETING DELIVERY AND TRACING OF THERAPEUTIC AGENTS - Disclosed herein is a method for treating a brain disease in which focused ultrasound and magnetic targeting are applied to a subject in need of such treatment, so that therapeutic agent-magnetic nanoparticle composites are directed across the blood-brain barrier to a designated locus inside the brain of the subject. Each of the composites includes a magnetic nanoparticle that is formed of an iron-based core and a shell encapsulating the iron-based core, and a therapeutic agent that is bound to the shell of the magnetic nanoparticle. The magnetic nanoparticle has a size ranging from 5 to 200 nm. The iron-based core has a crystalline structure that imparts the composites with a sufficiently high magnetization, thereby enhancing magnetic targeting of the composites to the designated locus inside the brain of the subject. The magnetic targeting treatment is conducted via a magnet providing a magnetic flux density not less than 0.18 T. | 04-19-2012 |
20120083031 | METHOD FOR TRACING GRAM-NEGATIVE BACTERIA INSIDE ANIMAL MODEL USING STABLE AND BIOLUMINESCENCE-BASED EXPRESSION SYSTEM THEREFOR - A method of creating a biotechnological product and an efficient and stable bio-luminescence vector which could be used for tracking Gram-negative bacteria when distributing inside animal body are provided. Through conjugation, this auto-luminescence vector can be easily transmitted from bacteria to bacteria among Gram-negative bacteria, and may facilitate bacteria to be luminescence-labeled for subsequently analyzing the dynamic change of bio-luminescent bacteria within animal body in vivo. This system includes a lacZ promoter-driven IuxABCDE, a high copy number of ColE1 replicon, and a high plasmid stability of the conjugative and broad host-ranged plasmid pSE34 from | 04-05-2012 |
20110014215 | GRANULYSIN AND USES THEREOF - Disclosed are uses of granulysin in methods of diagnosing or treating autoimmune disorders. | 01-20-2011 |